๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials in this register

19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
NCT06718972Meningeal Metastasis, Non-Small Cell Lung Cancer
Guangzhou Medical University
Observational
1,000
Guangzhou
2024-09-01
By invitation
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
NCT06864572Metastatic Prostate Cancer (mPC)
Peking Union Medical College Hospital
Phase EARLY_PHASE1
40
Beijing
2024-09-01
Recruiting
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
NCT06108414Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events
China National Center for Cardiovascular Diseases
Phase 4
4,374
Beijing
2024-09-01
By invitation
A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
NCT06647264Hepatocellular Carcinomas, Cholecystectomy, Laparoscopic, Hepatectomy, Pancreatoduodenectomy
Nanfang Hospital, Southern Medical University
Observational
1,500
Guangzhou
2024-09-01
Recruiting
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751914Colorectal Cancer (CRC)
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
By invitation
The Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) Targeting the Right Globus Pallidus Internus (GPi) for Motor Symptoms in Patients With PD
NCT06931483Temporal Interference Stimulation, Parkinson's Disease, the Right Globus Pallidus Internus, Motor Symptoms
Yanghua Tian
Not applicable
40
Hefei
2024-09-01
Recruiting
Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
NCT06464913Breast Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
152
Hangzhou
2024-09-01
Recruiting
Establishment of Screening Pathway for High-Risk Population of Type 1 Diabetes
NCT07468474Type 1 Diabetes Mellitus
Peking University First Hospital
Observational
340
Beijing
2024-09-01
Recruiting
A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors
NCT06150885Solid Tumor
Ever Supreme Bio Technology Co., Ltd.
Phase 1/2
60
2024-09-01
Not yet open
Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment
NCT06571214Infertility
Nanjing University
Phase 4
300
Nanjing
2024-09-01
Recruiting
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
NCT06752044Advanced NSCLC
The First Affiliated Hospital of Nanchang University
Not applicable
10
Nanchang
2024-09-01
Recruiting
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
NCT06595992Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,000
Hangzhou
2024-09-01
Active, closed
Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
NCT06614660Colorectal Cancer, Imaging, Metabolomics, Prognosis
First Affiliated Hospital of Chongqing Medical University
Observational
800
Chongqing
2024-09-01
Not yet open
Deep Brain Stimulation of the Dentate Nucleus for Motor Rehabilitation After Stroke
NCT06498934Stroke, Upper Extremity Paresis
Beijing Municipal Administration of Hospitals
Not applicable
52
Beijing
2024-09-01
By invitation
Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease
NCT06641843Kawasaki Disease, Cardiovascular Disease, Anomalous Origin of Coronary Artery
West China Second University Hospital
Observational
240
Chengdu
2024-09-01
Not yet open
Cervical Cytology DNA Methylation for Cervical Cancer Screening
NCT06557954Cervical Cancer, DNA Methylation, Cytology, Human Papillomavirus Infection
Lei Li
Observational
30,000
Beijing
2024-09-01
Recruiting
177Lu-TATE-RGD in Patients With SSTR2 and Integrin ฮฑVฮฒ3 Positive Tumors
NCT06632873SSTR2 and Integrin ฮฑVฮฒ3 Positive Tumors
Peking Union Medical College Hospital
Phase EARLY_PHASE1
10
Beijing
2024-09-01
Recruiting
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
NCT06852287Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2024-09-01
Recruiting
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
NCT06739265Peripheral T-cell Lymphoma
Peking Union Medical College Hospital
Phase 1/2
68
Beijing
2024-09-01
By invitation
Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy
NCT06748638Lactulose, Bowel Preparation
Haifeng Lan
Phase 4
444
Nanjing
2024-09-01
Recruiting
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
NCT06542796Hepatocellular Carcinoma, Immunotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Active, closed
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814Breast Cancer Metastatic
Zhimin Shao
Phase 3
307
Shanghai
2024-09-01
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Recruiting
EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia
NCT06642025Acute Myeloid Leukemia (AML), CAR-T
Zhimin Zhai
Phase EARLY_PHASE1
9
Hefei
2024-09-01
Recruiting
Analysis of Risk Factors for High Intraocular Pressure and Retinal Detachment Recurrence After Vitrectomy with Silicone Oil Tamponade in Retinal Detachment Patients
NCT06826573Rhegmatogenous Retinal Detachment
First Affiliated Hospital of Chongqing Medical University
Observational
65
Chongqing
2024-09-01
Recruiting
An Artificial Intelligence System for ROSE of EUS-FNA Sample: a Prospective, Multicenter, Diagnostic Study.
NCT06718725The Malignant Lesions and Non-malignant Lesions of Pancreas, Bile Duct, Liver and Lymph Node
Qilu Hospital of Shandong University
Observational
236
Jinan
2024-09-01
Active, closed
Clinical Efficacy and Survival Prediction Analysis of Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis
NCT07437638Liver Cirrhosis, Hepatic Encephalopathy, TIPS
The Second Affiliated Hospital of Chongqing Medical University
Observational
624
Chongqing
2024-09-01
Recruiting
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
NCT06612580Prostate Cancer (Adenocarcinoma)
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
10
Fuzhou
2024-09-01
Recruiting
Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
NCT06325774Localized Prostate Cancer
Changhai Hospital
Not applicable
20
Shanghai
2024-09-01
Not yet open
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
NCT06567080B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma
RenJi Hospital
Phase 1
15
Shanghai
2024-09
Not yet open
Perioperative Smoking Cessation in Elderly Chinese Undergoing Spinal Fusion
NCT06578611Spinal Fusion
The Second Hospital of Shandong University
Observational
2,000
Jinan
2024-09
Not yet open
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
NCT06548178HER2-positive Breast Cancer
Fudan University
Phase 2
242
Shanghai
2024-09
Not yet open
Research on the Impact of Chronic Pelvic Pain on Endometriosis
NCT06584760Chronic Pelvic Pain, Endometriosis
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Observational
60
Yiwu
2024-09
Recruiting
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
NCT06523673Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
104
Hangzhou
2024-09
Not yet open
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
NCT06469879Small Cell Lung Cancer Limited Stage
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
358
Hefei, Lanzhou, Nanjing, Tangshan, Harbin, Anyang, Xiangyang, Changsha
2024-09
Not yet open
Modified Water Vapor Thermal Therapy in Management of Patients With Large-volume Benign Prostatic Hyperplasia
NCT06596590Benign Prostatic Hyperplasia
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
76
Nanjing
2024-09
Recruiting
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
NCT06588764Graves Ophthalmopathy, Surgery
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09
Not yet open
Clinical Multicenter Randomized Controlled Study of Simultaneous Cognitive Training With Transcranial Magnetic Stimulation in the Treatment of VaD-MCI Patients
NCT06470113VaD-MCI
Xuanwu Hospital, Beijing
Not applicable
164
Beijing
2024-09
Not yet open
Application of Cheek Acupuncture in Vaginal Tightening Surgery
NCT06587711Pain Vulva
The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Not applicable
60
Beijing
2024-09
Not yet open
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NCT06567366Large B-cell Lymphoma
Ruijin Hospital
Phase 2
45
Shanghai
2024-09
Not yet open
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
NCT06585059Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-09
Not yet open
Clinical Multicenter Randomized Controlled Study of Non-invasive Brain Oscillation Modulation in the Treatment of AD-MCI Patients
NCT06470074AD-MCI
Xuanwu Hospital, Beijing
Not applicable
124
Beijing
2024-09
Not yet open
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
NCT06544460Ovarian Cancer
Fudan University
Phase 2
94
Shanghai
2024-08-31
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
NCT06554561PCNSL
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
43
Hanzhou
2024-08-31
Recruiting
Real-World Case Registry Study on Obesity
NCT07448090Obesity & Overweight, Obesity (Disorder)
Hubei Hospital of Traditional Chinese Medicine
Observational
10,000
Wuhan
2024-08-31
Recruiting
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT06554600Refractory or Relapsed Diffuse Large B Cell Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hanzhou
2024-08-31
Recruiting
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
NCT06787989Refractory Immune Cytopenia
iCell Gene Therapeutics
Phase 1
20
Chengdu
2024-08-31
Not yet open
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
NCT06518876POEMS Syndrome
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1
21
Beijing
2024-08-31
Recruiting
AR Training Versus Patching in Unilateral Amblyopia
NCT06498206Amblyopia Unilateral
Eye & ENT Hospital of Fudan University
Not applicable
114
Shanghai
2024-08-31
Recruiting
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
NCT06556199Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
38
Hanzhou
2024-08-31
Not yet open
Dual-focus Soft Contact Lenses for Controlling Rapid Progressive Myopia in Young Adults
NCT06528860Myopia
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
144
Shanghai
2024-08-31
Not yet open
HPP737 Substance Balance Study in Human
NCT06584058Psoriasis
Newsoara Biopharma Co., Ltd.
Not applicable
8
Suzhou
2024-08-30
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Recruiting
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
NCT06438822Cholangiocarcinoma
West China Hospital
Phase 2
51
Chengdu
2024-08-30
Recruiting
Effect of Developmental Care on Very Low Birth Weight Infants
NCT06515574Intervention
Children's Hospital of Fudan University
Not applicable
1,600
Shanghai
2024-08-30
Recruiting
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
NCT06337474Thrombocytopenia Alloimmune
Changzhou No.2 People's Hospital
Phase EARLY_PHASE1
9
Changzhou
2024-08-30
Recruiting
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
NCT06559371BREAST CANCER, PET/CT
Kunwei Shen
Observational
150
Shanghai
2024-08-30
Recruiting
EASi-KIDNEYโ„ข (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122Metastatic Castration-resistant Prostate Cancer
Full-Life Technologies UK Limited
Phase 1
50
Beijing, Shanghai
2024-08-30
Recruiting
Unveiling the Neural Mechanisms of 5-HT7 in Sleep Apnea Induced by Arousal Dysregulation
NCT06608888Obstructive Sleep Apnea
Beijing Tsinghua Chang Gung Hospital
Observational
140
Beijing
2024-08-30
Active, closed
A Study of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During Pregnancy
NCT07730762Insomnia
Xijing Hospital
Not applicable
200
Shanxi
2024-08-30
Active, closed
A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prognostic Value in Patients With NSCLC
NCT07530276NSCLC
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Not yet open
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1
90
Tianjin
2024-08-30
Recruiting
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
NCT06932744Paroxysmal Nocturnal Haemoglobinuria (PNH)
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
66
Beijing, Tianjin
2024-08-30
Recruiting
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06509009Nasopharyngeal Carcinoma by AJCC V8 Stage
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-30
Recruiting
High Definition Transcranial Direct Current Stimulation of Right Inferior Frontal Gyrus to Improve Social Impairments in Children with Autism
NCT06723522Autism Spectrum Disorder (ASD)
Central South University
Not applicable
60
Changsha
2024-08-30
Recruiting
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263Diffuse Large B-cell Lymphoma
Navy General Hospital, Beijing
Phase 2
240
Beijing
2024-08-30
Recruiting
Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia
NCT06561451Male Infertility, Teratospermia
ShangHai Ji Ai Genetics & IVF Institute
Not applicable
208
Shanghai
2024-08-30
Recruiting
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
NCT06932471Paroxysmal Nocturnal Hemoglobinuria
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
20
Beijing
2024-08-30
Recruiting
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
NCT06440057Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
78
Beijing
2024-08-29
Recruiting
Peginterferon ฮฑ-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429Essential Thrombocythemia
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment
NCT06497010Advanced Solid Tumor
The Affiliated Hospital Of Guizhou Medical University
Phase EARLY_PHASE1
40
Guiyang
2024-08-29
Recruiting
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer
Central South University
Observational
300
Changsha
2024-08-29
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Recruiting
Irinotecan Liposome in Combination With Capecitabine
NCT06578052Pancreatic Cancer
Junjie Hang
Not applicable
20
Shenzhen
2024-08-28
Recruiting
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
NCT06514027Non Small Cell Lung Cancer
BeBetter Med Inc
Phase 2
30
Guangzhou
2024-08-28
Active, closed
Nd:YAG Laser Effects on Subgingival Microbiota in Stage III-IV Periodontitis
NCT07061756Periodontitis
Rui He
Not applicable
240
Guangzhou
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Recruiting
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
NCT06780826Lung Cancer, Small Cell
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,430
Shanghai
2024-08-28
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Active, closed
Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis
NCT06667609Granulomatous Mastitis, Mastitis Chronic
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
320
Chaozhou, Dongguan, Guangzhou, Jiangmen, Shanwei
2024-08-28
By invitation
Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
NCT06574425Chronic Kidney Diseases, Hemodialysis
Dongliang Zhang, MD
Phase 4
80
Beijing
2024-08-28
Active, closed
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
NCT06439628Migraine
Chinese PLA General Hospital
Observational
3,000
Beijing, Hangzhou
2024-08-27
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects
NCT06576401Healthy Adult Subject
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
10
Suzhou
2024-08-27
Recruiting
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
NCT06617936Unresectable Non-small Cell Lung Cancer
Hua Zhang
Phase 2
36
Jinan
2024-08-27
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Recruiting
Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial
NCT06569953Acute Pain, Chronic Pain, Postoperative Pain
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
284
Chongqing
2024-08-26
Active, closed
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
NCT06566547Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
116
Hangzhou
2024-08-26
Recruiting
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06493864Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Shanghai
2024-08-26
Recruiting
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
NCT06561178Esophageal Squamous Cell Carcinoma
Sun Yat-Sen University Cancer Center
Observational
50
Guangzhou
2024-08-26
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, รœrรผmqi, Wuhan
2024-08-26
By invitation
Interventions on Non-prescription Dispensing of Antibiotics in Community Pharmacies
NCT06521892Non-Prescription Drug Misuse, Acute Respiratory Tract Infection
Huazhong University of Science and Technology
Not applicable
400
Wuhan
2024-08-25
Recruiting
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
NCT06566807Marginal Zone Lymphoma
Huai'an First People's Hospital
Phase 2
51
Huai'an
2024-08-25
Not yet open
Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors
NCT06550765Sarcoma, Soft Tissue, Sarcoma, Spindle Cell
Guangdong Provincial People's Hospital
Not applicable
98
Guangzhou
2024-08-25
Recruiting
Pathogenesis of Pediatric Obsessive-compulsive Disorder: Based on the Microbiota-gut-brain Axis
NCT06754319Obsessive-Compulsive Disorder, Tic Disorder
Shanghai Mental Health Center
Observational
125
Shanghai
2024-08-24
Recruiting
Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
NCT06458894Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
100
Yiwu
2024-08-24
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
NCT06503783Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Harbin, Shanghai
2024-08-24
Rows per page Showing 11701–11800 of 19052
Previous 116 117 118 119 120 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=118

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in China?

11,786 of the 19,052 studies in this register are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3,920 have not yet opened recruitment, 2,668 are active but closed to new participants, and 678 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.